Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of L-DOPA in AMD
NCT02873351Phase 2Withdrawn
- Sponsor
- Robert W. Snyder
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levodopa in age-related macular degeneration (AMD) (2 arms), sponsored by Robert W. Snyder. Primary endpoint: Treatment Emergent Adverse Events at 90 days. Planned start Sep 2019; status: withdrawn.
02
Drugs
levodopa
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02873351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873351.